Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05495321 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interleukin-2 on Active Dermatomyositis

StatusUnknown
PhasePhase 3
Started2022-12-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 5, 2022 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Enrolling by Invitation → Unknown
2022-12-02
Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v2
Trial statusRecruiting→Unknown
Study sitesdetails revised at 1 of 1 site
2022-11-30
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-09-01→confirmed 2022-12-01
Study title-4 characters
Interleukin-2 on RefractoryActive Dermatomyositis
2022-08-08
Original filing
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
Trial Details
NCT Number NCT05495321
Lead Sponsor Peking University People's Hospital
Conditions Dermatomyositis
Enrollment 240 participants
Start Date 2022-12-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2022-12-05